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Abstract
Background
Endometriosis is a common gynaecological condition that affects women and can lead to painful symptoms 
and infertility. It greatly affects women's quality of life, impacting on their careers, everyday activities, sexual 
and non-sexual relationships, and fertility. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most 
commonly used first-line treatment for endometriosis pain.
Objectives
To assess the effects of NSAIDs used for the management of pain in women with endometriosis compared to 
placebo, other NSAIDs, other pain management drugs, or no treatment.
Search methods
We searched the Cochrane Menstrual Disorders and Subfertility Group Trials Register (October 2016) 
published in the Cochrane Central Register of Controlled Trials (CENTRAL) (The Cochrane Library), 
MEDLINE (January 2008 to October 2016), EMBASE (date limited from 01 January 2016 to 19 October 2016 
as all earlier references are included in the CENTRAL output due to the Embase project), and the reference 
lists from relevant publications. No new randomised controlled trials were identified. Unless new evidence is 
identified in the future, this review will not be updated.
Selection criteria
We included all randomised controlled trials (RCTs) describing the use of NSAIDs in the treatment of 
endometriosis in women of all ages.
Data collection and analysis
In the 2009 update of this review, two review authors (CA and SH) independently read and extracted data from 
each of the included studies. Crossover trials were analysed using the inverse variance method in RevMan to 
calculate the odds ratio for binary outcomes.
Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis 02-Feb-2017
Review Manager 5.3 3
Main results
No new trials were identified in the 2016 update. This review includes two trials but only one trial, with 24 
women, was included in the analysis.
The overall risk of bias was unclear due to a lack of methodological detail. Using GRADE methodology the 
quality of the evidence was judged to be very low. Evidence was downgraded for risk of bias and for 
imprecision (wide confidence intervals and evidence based on a single small trial).
Comparing NSAIDs (naproxen) to placebo, there was no evidence of a positive effect on pain relief (odds ratio 
(OR) 3.27, 95% CI 0.61 to 17.69; one trial, 24 women; very low quality evidence) in women with 
endometriosis. There was also inconclusive evidence to indicate whether women taking NSAIDs (naproxen) 
were less likely to require additional analgesia (OR 0.12, 95% CI 0.01 to 1.29; one trial, 24 women; very low 
quality evidence) or to experience side effects (OR 0.46, 95% CI 0.09 to 2.47; one trial, 24 women; very low 
quality evidence) when compared to placebo.
No data were reported for quality of life, effect on daily activities, absence from work or school, women 
requiring more invasive treatment or participant satisfaction with treatment.
Authors' conclusions
Due to a lack of high quality evidence and lack of reporting of outcomes of interest for this review, we cannot 
make any judgement as to whether or not NSAIDs (naproxen) are effective in managing pain caused by 
endometriosis. There is no evidence on whether any individual NSAID is more effective than another. As 
shown in other Cochrane reviews, women using NSAIDs need to be aware of the possibility that these drugs 
may cause unintended effects.
Plain language summary
Non-steroidal anti-inflammatory drugs for treatment of pain in women with 
endometriosis 
What is the issue?
Endometriosis is a common gynaecological condition that affects women of childbearing age. It can lead to 
painful symptoms, including painful periods, pain during or after sexual intercourse, pelvic and lower 
abdominal pain, and infertility. It can greatly affect women's quality of life by impacting on their careers, 
everyday activities, sexual and non-sexual relationships, and fertility. Non-steroidal anti-inflammatory drugs 
(NSAIDs) are the most commonly used first-line treatment for endometriosis because they have few 
side-effects and many are available over the counter.
Why is this important?
Endometriosis is very common, but the diagnosis of it is difficult. In 2015, there were 1.8 billion women (aged 
15 to 49 years) in the world. It is estimated that up to 60% of women with painful periods have endometriosis, 
Endometriosis greatly affects women's quality of life, impacting on their careers, everyday activities, sexual 
and non-sexual relationships, and fertility. An unpublished survey conducted by a patient support organization 
in the United Kingdom, Endometriosis UK (www.endometriosis-uk.org/), found that 65% of women with 
endometriosis reported that their condition had negatively affected their employment. Ten per cent of women 
had to reduce their hours of work and 30% had not been able to continue in the same employment. As many 
as 16% of women were unable to continue in any employment and 6% needed to claim state benefits; thus, in 
addition to their feelings of loss as contributors to society, they became dependent upon others. This increased 
their feelings of low self-esteem. Endometriosis is seen as a significant public health issue because of the 
large number of women affected and the significant illnesses associated with this disease.
Non steroidal anti-inflammatory drugs are a form of pain relief readily available without prescription. They work 
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by preventing or slowing down the production of prostaglandins which helps to relieve the painful cramps 
associated with endometriosis. However, a Cochrane Review on the use of NSAIDs for women with painful 
periods found a higher risk of stomach upsets (such as nausea and diarrhoea) or other side effects (for 
example headache, drowsiness, dizziness, and dryness of the mouth), The purpose of this review was to 
compare all NSAIDs used in the treatment of the painful symptoms caused by endometriosis with placebo, 
other pain management drugs, or no treatment in order to evaluate their effectiveness and safety.
What evidence did we find?
We searched for new evidence in October 2016. No new randomised controlled trials were identified.
From previous updates, this review found limited evidence on whether NSAIDs (specifically naproxen) are 
effective for the treatment of pain caused by endometriosis. This review is also limited as it only includes one 
study which involved 20 women.The evidence is of very low quality, mainly due to poor reporting of the 
methods, and lack of precision in the findings for overall pain relief, unintended side effects of treatment, and 
the need for extra pain relief. The included trial did not report on quality of life, effect on daily activities, 
absence from work or school or participant satisfaction with treatment.
What does this mean?
The available evidence does not allow us to conclude whether or not any individual NSAID is more effective 
than another. As shown in other Cochrane reviews, women using NSAIDs need to be aware that NSAIDs may 
cause adverse effects such as nausea, vomiting, headache, and drowsiness. Unless new evidence is 
identified in the future, this review will not be updated.
Background
Description of the condition
Endometriosis is defined as the presence of endometrial tissue (stromal and glandular) outside the normal 
uterine cavity (Barbieri 1990). Endometriosis is a common gynaecological condition which can lead to painful 
symptoms and infertility. Symptoms may include dysmenorrhoea (painful periods), dyspareunia (pain during or 
after sexual intercourse), and pelvic or lower abdominal pain. A less common symptom is cyclical pain in other 
sites relating to endometriosis (Prentice 2003). Endometriosis can be divided into four stages of severity 
(stage I: minimal disease; stage IV: severe disease) as defined by the American Fertility Society's classification 
system (Canavan 2000). Staging does not correlate with the degree or severity of symptoms; it quantifies the 
amount of disease visible at laparoscopy. The link between the pain experienced by women and the extent of 
endometriosis is not well understood, and the severity of pain experienced does not, therefore, always directly 
correlate with severity of the endometriosis (Kauppila 1985). Even when endometriosis is diagnosed, it may 
not be the cause of a woman's symptoms as the mechanism by which pain is caused is not fully understood.
Endometriosis greatly affects women's quality of life, impacting on their careers, everyday activities, sexual 
and non-sexual relationships, and fertility (Davies 2003; Jones 2002). An unpublished survey conducted by a 
patient support organization in the United Kingdom, Endometriosis UK (www.endometriosis-uk.org/), found 
that 65% of women with endometriosis reported that their condition had adversely affected their employment. 
Ten per cent of women had to reduce their hours of work and 30% had not been able to continue in the same 
employment. As many as 16% of women were unable to continue in any employment and 6% needed to claim 
state benefits; thus, in addition to their feelings of loss as contributors to society, they became dependent upon 
others. This increased their feelings of low self-esteem. 
 
Prevalence  
The exact prevalence of endometriosis is unknown. However, endometriosis is a significant problem for a 
great number of women and has high socio-economic costs (Prentice 2003). Endometriosis primarily affects 
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women of reproductive age (that is women who are menstruating). In women experiencing no symptoms, the 
prevalence of endometriosis has been estimated to be from 2% to 22% depending on the diagnostic criteria 
used and the populations studied. In women with painful periods, the prevalence of endometriosis ranges from 
40% to 60%; and in women with subfertility, it is from 20 to 30%. The severity of symptoms and the probability 
of diagnosis increases with age, peaking at about 40 years old (Berube 1998; Vessy 1992). In the year 2000, 
there were 1.5 billion women (aged 15 to 49 years) in the world. A 1% prevalence means, therefore, that there 
could be 15 million women with endometriosis worldwide; assuming a 20% prevalence implies that there are 
300 million women with endometriosis. The actual figure must lie somewhere in between but is unknown as 
studying the epidemiology of endometriosis is difficult (Kennedy 2003).
Diagnosis  
Laparoscopy is considered the 'gold standard' for diagnosis of endometriosis (Canavan 2000; rAFS 1985). 
However, endometriosis may also be diagnosed (or presumed) based on a description of symptoms by the 
woman (and which may be suspected by the practitioner from the history, pelvic examination, and other tests 
such as ultrasound, magnetic resonance imaging (MRI), and the CA-125 blood test). However, examination, 
test findings, and the presence or absence of a classic history and symptoms cannot either confirm or rule out 
endometriosis.
Description of the intervention
There are many ways to treat the symptoms of endometriosis but to treat the underlying disease often requires 
repeated medical or surgical interventions. Management of endometriosis is varied. Medical treatments for 
endometriosis include oral contraceptives, progestagens, testosterone derivatives, and 
gonadotrophin-releasing hormone (GnRH) agonists (Rice 2002). Surgical treatments include ablative 
techniques (destroying the endometriosis with energy such as laser or electricity) and excision (using scissors, 
electricity, or laser). This surgical approach aims to relieve symptoms whilst conserving reproductive function. 
More radical surgery in the form of hysterectomy, removal of the ovaries (oophorectomy), or both may also be 
performed. Conventional medical and surgical treatments for endometriosis aim to remove or decrease 
deposits of ectopic endometrium (tissue like the lining of the uterus but found outside the uterus) 
(Barbieri 1990). Non-steroidal anti-inflammatory drugs (NSAIDs) are most commonly used as a simple first-line 
treatment for endometriosis because they have few side-effects and many are available over the counter. They 
do not remove or decrease the deposits of ectopic endometrium. NSAIDs may also act on local cytokines 
within the actual endometriotic deposits, as well as acting as analgesics.
How the intervention might work
Non-steroidal anti-inflammatory drugs (NSAIDs) work by decreasing the amount of pain experienced by 
women. NSAIDs (including COX2 inhibitors) inhibit prostaglandin production. Prostaglandins are locally 
produced chemicals that are believed to be responsible for causing the pain of endometriosis. NSAIDs 
purchased over the counter may be taken in doses that are insufficient to relieve pain. However, NSAIDs taken 
in high doses have the potential to cause side-effects. A Cochrane review of 31 studies that compared NSAIDs 
versus placebo for primary dysmenorrhoea found a statistically significant increased risk of adverse effects in 
the gastrointestinal (for example nausea and diarrhoea) and nervous (for example headache, drowsiness, 
dizziness, and dryness of the mouth) systems (Marjoribanks 2015). NSAIDs are analgesics which inhibit the 
cyclo-oxygenase (COX) enzymes thereby inhibiting the production of prostaglandins and alleviating cramps 
(Dawood 1986; Marjoribanks 2015). The first of the drugs with this mode of action was aspirin (acetylsalicylic 
acid), which was introduced in 1899. However, the term NSAID was not used until the 1950s when 
phenylbutazone was developed. Since then NSAIDs have become more widely used (Hart 1984; Marjoribanks 
2015).
Why it is important to do this review
Endometriosis is seen as a significant public health issue because of the large number of women affected and 
the significant illnesses associated with this disease (Murphy 2002). NSAIDs are widely used drugs that are 
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readily available (both over the counter and on prescription). The purpose of this review was to compare all 
NSAIDs used in the treatment of the painful symptoms caused by endometriosis with placebo, other pain 
management drugs, or no treatment in order to evaluate their effectiveness and safety.
Objectives
To assess the effects of NSAIDs (of any type, dose, or duration) used for the management of pain in women 
with endometriosis compared with placebo, other NSAIDs, other pain management drugs, or no treatment.
Methods
Criteria for considering studies for this review
Types of studies
We included all randomised controlled trials describing the use of NSAIDs in the treatment of endometriosis in 
women of all ages. Crossover trials were included, as the crossover is a valid design in this context.
Types of participants
We included women with any stage or severity of endometriosis. Endometriosis was diagnosed by 
visualisation (for example laparoscopy or laparotomy) or was a suspected diagnosis based on the history and 
pelvic examination and other tests such as ultrasound, MRI, and the CA-125 blood test. We excluded women 
with chronic pelvic pain which was known to be due to causes other than endometriosis.
Types of interventions
We included all randomised controlled trials involving NSAIDs as a treatment for pain for women with 
endometriosis versus placebo, other NSAIDs, other drug pain management approaches, or no treatment. We 
considered randomised controlled trials describing NSAIDs of any type and administered at any dose, 
frequency, treatment duration, or by any type of administration.
Types of outcome measures
Data on each of the following outcomes were recorded from included trials, where available. 
 
Primary outcomes
Pain relief (measured either by visual analogue scale (VAS), other validated scales, or as a dichotomous 
outcome, for example improved or not improved)
Unintended effects from treatment (incidence and duration of total side-effects, and type of side-effects)
Secondary outcomes
Quality of life (measured using a validated scale, for example the SF36)
Effect on daily activities (measured as proportion of women who reported activity restriction)
Absence from work or school (measured as proportion of women reporting absences from work or 
school, and also as hours or days of absence as a more selective measure)
Number of women requiring more invasive treatment (for example laparoscopic surgery), and length of 
follow up
Requirements for additional medication (measured as proportion of women requiring analgesics (not 
NSAIDs) additional to their assigned treatment)
Participant satisfaction with treatment (measured as proportion of women who reported improvements 
and satisfaction with their treatment)
Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis 02-Feb-2017
Review Manager 5.3 7
Search methods for identification of studies
We searched for all published and unpublished RCTs of the use of NSAIDs for the treatment of pain in women 
with endometriosis, without language restriction and in consultation with the Gynaecology and Fertility Group 
(CGF) Information Specialist.
Electronic searches
We searched the Cochrane Gynaecology and Fertility Group (CGF) Specialised Register of Controlled Trials 
(October 2016), the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, 
PsycINFO, and CINAHL to identify all publications which described, or might describe, randomised trials of any 
NSAID in the treatment of endometriosis. Search strategies are outlined in the appendices (Appendix 1; 
Appendix 2; Appendix 3; Appendix 4; Appendix 5; Appendix 6).
No new randomised controlled trials were identified.
Searching other resources
The World Health Organization International Clinical Trials Registry Platform (ICTRP) 
(http://www.who.int/ictrp/network/en/index.html), and the US National Institute of Health trial register 
Clinicaltrials.gov (http://www.clinicaltrials.gov) were also searched for ongoing studies using the terms 
'endometriosis' AND 'non steroidal anti inflammatory', OR 'NSAIDs'. No ongoing trials were identified that were 
relevant to this review. References in relevant reports were checked to identify additional studies.
Data collection and analysis
Selection of studies
In 2016 support staff from the Cochrane Gynaecology and Fertility Group screened the titles and abstracts of 
all retrieved records to identify possible trials for inclusion in the review. Full copies of the reports were 
obtained for each of the records not rejected. No new studies for inclusion were identified.
Data extraction and management
In previous updates, data extraction was performed independently by two review authors (CA and SH) using a 
prespecified data extraction form. Any disagreements were resolved by discussion. Information was extracted 
from each included trial on: 
(1) characteristics of trial participants (including age, stage and severity of disease, and method of diagnosis), 
and the trial's inclusion and exclusion criteria; 
(2) type of intervention (including type, dose, duration, and frequency of the NSAID versus placebo; the type, 
dose, duration, and frequency of another NSAID; another pain management drug; or no treatment); 
(3) type of outcome measure (including the level of pain reduction, improvement in quality of life score (using a 
validated scale), effect on daily activities, absence from work or school, length of follow up, unintended effects 
of treatment, number of women requiring more invasive treatment, and length of follow up).
Where data for a trial were insufficient or missing, we sought information from the named contact author of the 
trial. We attempted to contact Dr Kauppila but have been unable to elicit a response.
Assessment of risk of bias in included studies
In previous updates, two review authors independently assessed the included studies for risk of bias using the 
Cochrane risk of bias tool (Higgins 2011) to assess:
Selection (random sequence generation and allocation concealment)
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Pefromance (blinding of participants and personnel)
Detection (blinding of outcome assessors)
Attrition (incomplete outcome data)
Reporting (selective reporting)
Other bias
Judgements were assigned as recommended in the Cochrane Handbook section 8.5 (Higgins 2011) 
Disagreements were resolved by discussion. We described all judgements and presented the conclusions in 
the Risk of Bias table.
Measures of treatment effect
Both of the trials identified for inclusion in this review were crossover trials. Only one trial (Kauppila 1985) 
contained sufficient information to be included in a meta-analysis. This trial was analysed using the method 
described by Elbourne and colleagues (Elbourne 2002), analysing information from both parts of the 
two-period, two-treatment crossover trial. For each binary outcome the log odds ratio, as a measure of the 
different effects of the two treatments, was calculated with its corresponding standard error. This information 
was then applied in the meta-analysis using the inverse variance method available in RevMan.
Unit of analysis issues
Statistical advice was sought regarding the analysis of crossover trials, to facilitate the appropriate inclusion of 
crossover data in meta-analysis.
Dealing with missing data
We analysed the data on an intention-to-treat basis as far as possible (i.e. including all randomised 
participants in analysis, in the groups to which they were randomised. Attempts were made to obtain missing 
data from the original trialists but these were unobtainable.
Assessment of heterogeneity
We intended to consider whether the clinical and methodological characteristics of the included studies were 
sufficiently similar for meta-analysis to provide a clinically meaningful summary. We intended to assess 
statistical heterogeneity by the measure of the I2, with an I2 measurement greater than 50% taken to indicate 
substantial heterogeneity (Higgins 2011)
Assessment of reporting biases
In view of the difficulty of detecting and correcting for publication bias and other reporting biases, we aimed to 
minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for 
duplication of data. If ten or more studies had been included in the analysis, we would have used a funnel plot 
to explore the possibility of small study effects (a tendency for estimates of the intervention effect to be more 
beneficial in smaller studies).
Data synthesis
We carried out statistical analysis using the Review Manager software (RevMan 2014).
Subgroup analysis and investigation of heterogeneity
Subgroup analyses, by analysing women with endometriosis and type of NSAID or type of diagnosis (by direct 
visualisation or just presumed), were not conducted as there were insufficient data. The decision about 
whether or not to combine the results of individual trials was dependent on an assessment of heterogeneity. In 
the first instance the trials were assessed for clinical and methodological homogeneity. Where trials were 
judged to be sufficiently homogeneous, it had been decided that a meta-analysis of these trials would be 
carried out and statistical heterogeneity investigated. In the event, this was not carried out.
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Sensitivity analysis
We intended conducting sensitivity analyses for the primary outcomes to determine whether the conclusions 
were robust to arbitrary decisions made regarding the eligibility and analysis. However, there was insufficient 
data to enable sensitivity analysis to be conducted.
Results
Description of studies
Results of the search
In earlier updates of this review, searches identified 53 citations. Of these, full papers were obtained for eight 
possibly relevant trials. Only two trials were identified which met the inclusion criteria for this review. One trial 
was identified which was potentially relevant but was then excluded. The other five possibly relevant trials 
were of naproxen used specifically for dysmenorrhoea, not endometriosis. No ongoing trials were identified.
Included studies
The first trial (Kauppila 1979) was a two-period, four-treatment crossover trial comparing indomethacin (25 mg, 
three times per day), acetylsalicylic acid (500 mg, three times per day), tolfenamic acid (200 mg, three times 
per day), and placebo (three times per day) in 24 women with symptomatic endometriosis (stage and severity 
were not described). Each woman received each of the four drugs for two menstrual cycles each but it was not 
clear how the women were randomised. Women were diagnosed with endometriosis by laparoscopy or pelvic 
examination.
The second trial (Kauppila 1985) was a two-period, two-treatment crossover trial comparing naproxen sodium 
(275 mg, four times per day) with placebo (four times per day) in 24 women with endometriosis as classified by 
the American Fertility Society (mild endometriosis, n = 7; moderate endometriosis, n = 8; severe 
endometriosis, n = 6). Women were diagnosed by pelvic examination, history of menstrual distress, or by 
direct visualisation of pelvic regions at laparoscopy or laparotomy. Each woman received either naproxen 
sodium for two menstrual cycles followed by placebo for two menstrual cycles, or placebo for two menstrual 
cycles followed by naproxen sodium for two menstrual cycles.
Excluded studies
The excluded trial (Cobellis 2004) assessed the use of the COX2-specific inhibitor (rofecoxib) for the 
management of pain related to endometriosis. However, this drug was withdrawn from the marketplace in 
November 2004 on the grounds of safety and, therefore, it is inappropriate to assess the efficacy of the 
product in this review. If the drug is re-launched then this decision will be reviewed when the review is updated.
Risk of bias in included studies
Information on potential risk of bias for each of the included studies is summarised in a risk of bias table and 
an overall summary provided in Figure 1; and Figure 2.
Allocation (selection bias)
Neither of the trials (Kauppila 1979; Kauppila 1985) provided information about the method of randomisation 
or concealment of allocation sequence. One trial (Kauppila 1985) described how each woman received either 
naproxen sodium for two menstrual cycles followed by placebo for two menstrual cycles, or placebo for two 
menstrual cycles followed by naproxen sodium for two menstrual cycles. In Kauppila 1979 each woman 
received each of four drugs (indomethacin, acetylsalicylic acid, tolfenamic acid, and placebo) for two menstrual 
cycles each, but it was not clear how the women were randomised.
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Blinding (performance bias and detection bias)
Both of the trials (Kauppila 1979; Kauppila 1985) were described as double blind and one trial (Kauppila 1985) 
specifically mentioned the drugs being dispensed in identical capsules. No information was provided about the 
blinding of the outcome assessors or data analysers for either trial.
Incomplete outcome data (attrition bias)
In the trial Kauppila 1979, 24 women were randomised but only 18 were included in the analysis. The reasons 
for loss to follow up were not given. In the trial, Kauppila 1985, 24 women were randomised and only 20 were 
included in the analysis. The reasons given for loss to follow up included pregnancy (n = 1), psychiatric 
problems (n = 1), and unknown reasons (n = 2).
In the trial Kauppila 1979, data were presented graphically for each menstrual cycle (144 cycles) and not per 
woman in the trial. It was, therefore, not possible to link each of the menstrual cycles from one treatment 
against the corresponding menstrual cycle from an alternative treatment. It was also not possible to link the 
two menstrual cycles for each woman with each treatment. It appears as though the authors, in carrying out 
their analysis, did not take account of the pairing within each treatment group. For these reasons this trial was 
not included in the overall analysis.
Selective reporting (reporting bias)
Both included trials (Kauppila 1979; Kauppila 1985) were judged as having an unclear risk of bias because 
neither trial clearly prespecified primary and secondary outcomes.
Other potential sources of bias
The included trials were both judged as having an unclear risk of bias due to insufficient information to enable 
a judgement of low risk of bias.
Effects of interventions
Comparison of Naproxen Sodium versus Placebo.
Primary outcomes
1.1 Overall pain relief
One trial reported data on overall pain relief (Kauppila 1985). There was no evidence of a difference between 
naproxen sodium (275 mg, four times a day) and placebo in producing excellent to moderate relief of pain 
caused by endometriosis (Odds Ratio (OR) 3.27, 95% CI 0.61 to 17.69; 1 RCT, 24 women; very low quality 
evidence).
1.2 Unintended effects of treatment
One trial reported data on unintended effects of treatment (Kauppila 1985). This showed no evidence of a 
difference between women taking naproxen sodium and experiencing unintended effects of treatment 
compared to when they were taking placebo and experiencing unintended effects of treatment (OR 0.46, 95% 
CI 0.09 to 2.47; 1 RCT, 24 women; very low quality evidence). The unintended effects of treatment reported 
while taking naproxen sodium (n = 4) included fatigue, lightheadedness, eye lid swelling, and chest pain. The 
unintended effects of treatment reported while taking placebo (n = 7) included hypomenorrhoea (losing a small 
amount of menstrual blood but menstrual cycles still regular), diarrhoea, increased diuresis, headache, 
epigastric pain, nausea and vomiting, tremor, and dizziness.
Secondary outcomes
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1.3 Requirement for additional medication
One trial (Kauppila 1985) provided data on the need for supplementary analgesia. This showed no evidence of 
a difference between women taking naproxen sodium and requiring supplementary analgesia compared to 
when they were taking placebo and requiring supplementary analgesia (OR 0.12, 95% CI 0.01 to 1.29; 1 RCT, 
24 women) for pain caused by endometriosis.
The included trial did not report on the other secondary outcomes of this review (quality of life, effect on daily 
activities, absence from work or school, number of women requiring more invasive treatment, or participant 
satisfaction with treatment).
Discussion
Summary of main results
Despite rigorous searches, we only identified two randomised controlled trials comparing NSAIDs with placebo 
in the treatment of women with endometriosis. There was no evidence of a difference between NSAIDs and 
placebo for overall pain relief, unintended effects of treatment or requirement for additional medication 
(Summary of findings table 1). No data were report on the other secondary outcomes of this review (quality of 
life, effect on daily activities, absence from work or school, number of women requiring more invasive 
treatment, or participant satisfaction with treatment). The evidence is surprising given that NSAIDs are widely 
prescribed and are bought over the counter for the treatment of pain caused by endometriosis. In comparison, 
there is much literature suggesting the use of NSAIDs as a treatment for primary dysmenorrhoea. It is likely 
that prostaglandins are involved in pain causation in both groups of patients. A recent Cochrane review 
(Marjoribanks 2015) showed evidence that NSAIDs are an effective treatment for pain caused by primary 
dysmenorrhoea, although women using NSAIDs need to be aware of the risk of unintended effects of 
treatment.
Overall completeness and applicability of evidence
Due to the lack of randomised controlled trials in the area of NSAIDs as a treatment for endometriosis, we are 
unable to comment on many of the outcomes which are important to women who have endometriosis, such as 
quality of life, effect on daily activities, and absence from school or work. Only four NSAIDs (naproxen sodium, 
indomethacin, acetylsalicylic acid, and tolfenamic acid) were assessed for the treatment of endometriosis 
(Kauppila 1985; Kauppila 1979). One trial (Kauppila 1979) analysed three of these NSAIDs (indomethacin, 
acetylsalicylic acid, and tolfenamic acid) but was not analysed in this review as it had serious methodological 
flaws. However, there are many other prescribed and over-the-counter NSAIDs available. No evidence was 
found to support the use of these in controlling pain caused by endometriosis.
The one remaining trial (Kauppila 1985) included and analysed in this review showed no evidence of an effect 
when comparing NSAIDs (naproxen sodium) with placebo in the management of pain caused by 
endometriosis. There was inconclusive evidence to indicate whether or not women taking NSAIDs were less 
likely to take supplementary analgesia than those women taking placebo. We believe this is most likely 
because the trial was very small (randomising only 24 women) and, therefore, would recommend caution when 
applying these results to a larger population.
There was also inconclusive evidence to show whether or not women taking NSAIDs were more likely to 
experience unintended effects of treatment compared with women taking placebo. Four women experienced 
unintended effects of treatment whilst taking naproxen sodium compared with seven women while taking 
placebo. It is possible that the unintended effects reported when women were randomised to placebo could 
have been related to the pain caused by endometriosis rather than to the placebo itself. However, the small 
number of women included in this trial make it difficult to draw any firm conclusions.
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Quality of the evidence
The risk of bias was judged to be unclear due to lack of methodological detail. The overall quality of the 
evidence using GRADE methodology was judged to be of very low quality due to unclear risk of bias, 
imprecision with wide confidence intervals and evidence being based on a single small study (Summary of 
findings table 1).
Potential biases in the review process
The authors believe they have minimised the potential biases in the review process by searching published 
and unpublished literature with no restrictions on date of publication or language. We were unable to judge the 
potential effect of publication bias as less than ten trials were identified.
Agreements and disagreements with other studies or reviews
Despite the findings of this review, it is important to highlight the findings of another Cochrane review of 
NSAIDs for the management of pain caused by primary dysmenorrhoea (Marjoribanks 2015), which showed 
that there is insufficient evidence to determine which (if any) individual NSAID is the most safe and effective 
treatment.
Authors' conclusions
Implications for practice
There is inconclusive evidence to show whether non-steroidal anti-inflammatory drugs (NSAIDs) (naproxen 
sodium) are effective for the treatment of pain caused by endometriosis. There is no evidence to suggest 
whether any individual NSAID is more effective than others. As shown in other Cochrane reviews, women 
using NSAIDs need to be aware of the possibility that these drugs may cause unintended effects.
Implications for research
The two included studies were conducted in the late 1970s and mid 1980s, and both randomised small 
numbers of women. A systematic search of the literature has found no randomised controlled trials comparing 
NSAIDs with other treatments. One trial compared different types of NSAIDs; however, this had 
methodological limitations. More trials with larger numbers of women are needed, ensuring they are of a robust 
design and assessing and reporting the outcomes that are important to women with endometriosis (for 
example quality of life, effects on daily activities, absence from school or work, and need for a more invasive 
treatment).
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Differences between protocol and review
The original review had six primary outcomes. In 2016 these were reduced to two:
Pain relief (measured either by visual analogue scale (VAS), other validated scales, or as a dichotomous 
outcome, for example improved or not improved)
Unintended effects from treatment (incidence and duration of total side-effects, and type of side-effects)
The remaining primary outcomes became secondary outcomes.
Published notes
Characteristics of studies
Characteristics of included studies
Kauppila 1979
Methods Trial design: 2-period, 4-treatment crossover trial 
Participants 24 women randomised; 18 analysed. Mean age 33 (22-43) years
Inclusion criteria: women with symptomatic endometriosis (stage and severity not 
described). Women were diagnosed by laparoscopy (n=13) and by pelvic 
examination (n=5) 
Exclusion criteria: not clear 
Setting: Finland
Timing: Unclear
Interventions Group 1 - indomethacin 25 mg given 3 x daily for 2 menstrual cycles then 
crossover to acetylsalicylic acid, tolfenamic acid, and placebo for 2 menstrual 
cycles each (n = 6) 
 
Group 2 - acetylsalicylic acid 500 mg given 3 x daily for 2 menstrual cycles then 
crossover to tolfenamic acid, placebo, and indomethacin for 2 menstrual cycles 
each (n = 6).
 
Group 3 - tolfenamic acid 200 mg given 3 x daily for 2 menstrual cycles then 
crossover to placebo, indomethacin, and acetylsalicylic acid for 2 menstrual 
cycles each (n = 6) 
Group 4 - placebo was given 3 x daily for 2 menstrual cycles then crossover to 
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indomethacin, acetylsalicylic acid, and tolfenamic acid for 2 menstrual cycles 
each (n = 6) 
Outcomes These were self reported using a questionnaire completed by the patient 
immediately after each menstrual cycle
Pain relief: pelvic pain, lower back pain, pain in walking, dyspareunia, pain on 
defecation, headache; number not reported but described more common with 
placebo and indomethacin 
Quality of life: not reported 
Effect on daily activities: not reported 
Absence from work or school: not reported 
Unintended effects from treatment: gastro-intestinal complaints (nausea and 
vomiting), number not reported but described as more common with 
indomethacin; psychic complaints (insomnia and nervousness), number not 
reported but described as more common with indomethacin 
No. of women requiring more invasive treatment: not reported 
Requirements for additional medication: not reported 
Patient satisfaction with treatment: not reported
Notes Drugs for use in the trial were provided by Medica Ltd, Helsinki, Finland. "The 
authors wish to thank Medica Ltd, Helsinki, Finland for the drugs."
Risk of bias table
Bias Authors' judgement Support for judgement
Random sequence 
generation (selection bias)
Unclear risk Not described.
Allocation concealment 
(selection bias)
Unclear risk Not described.
Blinding (performance bias 
and detection bias)
Unclear risk "placebo-controlled double-blind trial"
Incomplete outcome data 
(attrition bias)
Low risk "Twenty-four patients...volunteered for this study. Eighteen 
women completed the trial; the remaining six terminated 
treatment for a variety of personal reasons."
Selective reporting 
(reporting bias)
Unclear risk Prespecified primary and secondary outcomes were not clearly 
defined.
Other bias Unclear risk Insufficient information provided to enable a judgement of low risk 
of bias.
Kauppila 1985
Methods Trial design: 2-period, 2-treatment crossover trial 
 
Participants 24 women randomised; 20 analysed. Mean age Group 1 32 years, Group 2 35 
years. 
Inclusion criteria: women with endometriosis classified by the American Fertility 
Society (mild endometriosis n=7; moderate endometriosis n=8; severe 
endometriosis n=6) Women were diagnosed by pelvic examination, history of 
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menstrual distress, and by direct visualisation of pelvic regions at laparoscopy or 
laparotomy 
Exclusion criteria: not clear 
Setting: Finland
Timing: Unclear
Interventions Group 1 - naproxen sodium (NSAID) 275 mg (102 tablets) 4 x daily for 2 
menstrual cycles, then crossover to placebo for 2 menstrual cycles (n = 12) 
Additional interventions: additional analgesia was allowed if no relief after the first 
two doses of NSAID
Group 2 - placebo was given for 2 menstrual cycles, then crossover to naproxen 
sodium (NSAID) for 2 menstrual cycles (n = 12). Additional interventions: 
additional analgesia was allowed if no relief after first two doses
Outcomes These were all self reported using a questionnaire completed by the patient 
immediately after each menstrual cycle
Pain relief: measured after each menstrual cycle (score 3 to -1) 
Quality of life: not reported 
Effect on daily activities: activity of patient (score 4 to 0) 
Absence from work or school: not reported 
Unintended effects from treatment: fatigue, lightheadedness, eye lid edema, and 
chest pain (n=4 while taking naproxen sodium); hypomenorrhoea, diarrhoea, 
increased diuresis, headache, epigastric pain, nausea and vomiting, tremor, and 
dizziness (n=7 while taking placebo) 
No. of women requiring more invasive treatment: not reported 
Requirements for additional medication: supplemental analgesia was more 
common in the placebo group (14) than in the NSAID group (2) 
Patient satisfaction with treatment: not reported
Notes Drugs used in the trial were supplied by Syntex Research, Maidenhead, England. 
"The study drugs were kindly supplied by Syntex Research, Maidenhead, 
England."
Risk of bias table
Bias Authors' judgement Support for judgement
Random sequence 
generation (selection bias)
Unclear risk Not described.
Allocation concealment 
(selection bias)
Unclear risk Not described.
Blinding (performance bias 
and detection bias)
Low risk "The study was conducted according to a randomized, 
double-blind, four-period crossover design."
Incomplete outcome data 
(attrition bias)
Low risk "Twenty-four patients...entered the present study...One patient 
became pregnant before the first treatment, one patient had 
psychiatric problems that rendered her responses unreliable, and 
two patients were lost to follow-up for unknown reasons during 
the trial."
Selective reporting 
(reporting bias)
Unclear risk Prespecified primary and secondary outcomes were not clearly 
defined.
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Other bias Unclear risk Insufficient information provided to enable a judgement of low risk 
of bias.
Footnotes
Characteristics of excluded studies
Cobellis 2004
Reason for exclusion This trial assessed the use of the COX2-specific inhibitor (rofecoxib) for the 
management of pain related to endometriosis. However this drug was withdrawn 
from the marketplace in November 2004 on safety grounds and therefore it is 
inappropriate to assess the efficacy of the product in this review. If the drug is re 
launched this decision will be reviewed when the review is updated.
Footnotes
Characteristics of studies awaiting classification
Footnotes
Characteristics of ongoing studies
Footnotes
Summary of findings tables
1 NSAID compared to placebo for pain in women with endometriosis
NSAID compared to placebo for pain in women with endometriosis
Patient or population: Women with endometriosis 
Setting: Finland 
Intervention: Non-steroidal anti-inflammatory drugs (NSAIDs) 
Comparison: placebo
Outcomes Anticipated absolute 
effects* (95% CI)
Relative 
effect 
(95% CI)
 of 
participa
nts 
(studies)
Quality of 
the evidence 
(GRADE)
Com
ments
Risk with 
placebo
Risk with 
NSAID
Pain relief 
assessed with: Overall pain relief 
score follow up: median 2 months
50 per 100 77 per 100
 
(38 to 95)
OR 3.27 
(0.61 to 
17.69)
24 
(1 RCT)
  
VERY LOW 1 
2
Unintended effects from treatment 58 per 100
39 per 100
 
(11 to 78)
OR 0.46 
(0.09 to 
2.47)
24 
(1 RCT)
  
VERY LOW 1 
2
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Quality of life - not reported - - - - -
Effect on daily activities - not reported - - - - -
Absence from work or school - not 
reported
- - - - -
Number of women requiring more 
invasive treatment - not reported
- - - - -
Requirements for additional medication 83 per 100 38 per 100
 
(5 to 87)
OR 0.12 
(0.01 to 
1.29)
24 
(1 RCT)
  
VERY LOW 1 
2
Participant satisfaction with treatment 
- not reported
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the 
comparison group and the relative effect of the intervention (and its 95% CI). 
 
CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;
GRADE Working Group grades of evidence 
High quality: We are very confident that the true effect lies close to that of the estimate of the effect 
Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to 
the estimate of the effect, but there is a possibility that it is substantially different 
Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different 
from the estimate of the effect 
Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be 
substantially different from the estimate of effect
Footnotes
1 Downgraded one level due to overall unclear risk of bias for included trial.
2 Downgraded two levels for imprecision because confidence interval is wide, consistent with benefit and harm 
and evidence based on a single small trial.
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Data and analyses
1 NSAID versus placebo
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate
1.1 Overall pain relief 1 odds ratio (IV, Fixed, 95% CI) 3.27 [0.61, 17.69]
1.2 Unintended effects of 
treatment
1 odds ratio (IV, Fixed, 95% CI) 0.46 [0.09, 2.47]
1.3 Requirements for additional 
medication
1 odds ratio (IV, Fixed, 95% CI) 0.12 [0.01, 1.29]
 
Figures
Figure 1
Methodological quality graph: review authors' judgements about each methodological quality item presented 
as percentages across all included studies.
Figure 2
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Methodological quality summary: review authors' judgements about each methodological quality item for each 
included study.
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Appendices
1 Cochrane Gynaecology and Fertility Group search strategy
From inception to 19 October 2016
Procite platform
Keywords CONTAINS "endometriosis" or "endometriosis scores" or "pelvic pain" or "dyschezia" or 
"dyspareunia" or Title CONTAINS "endometriosis" or "endometriosis scores" or "pelvic pain" or "dyschezia" or 
"dyspareunia"
AND
Keywords CONTAINS "nonsteroidal" or "NSAID" or "NSAIDs" or "mefenamic acid" or "Naprosyn" or 
"naproxen" or "Ibuprofen" or "Flurbiprofen " or "Meclofenamic Acid" or "Meclofenamate" or "diclofenac" or 
"acetylsalicylic" or "Aspirin" or "indomeixin" or "indometacin" or "indomethacin"or "Ketoprofen" or "Piroxicam" 
or "Flufenamic Acid" or "nimesulide"or "COX-2 inhibitors" or "cyclooxygenase" or Title CONTAINS 
"nonsteroidal" or "NSAID" or "NSAIDs" or "mefenamic acid" or "Naprosyn" or "naproxen" or "Ibuprofen" or 
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"Flurbiprofen " or "Meclofenamic Acid" or "Meclofenamate" or "diclofenac" or "acetylsalicylic" or "Aspirin" or 
"indomeixin" or "indometacin" or "indomethacin"or "Ketoprofen" or "Piroxicam" or "Flufenamic Acid" or 
"nimesulide"or "COX-2 inhibitors" or "cyclooxygenase" (31 hits)
2 CENTRAL CRSO search strategy
From inception to 19 October 2016
CRSO web platform
#1 MESH DESCRIPTOR Endometriosis EXPLODE ALL TREES 509
#2 Endometriosis:TI,AB,KY 1127
#3 dyspareunia*:TI,AB,KY 483
#4 dyschezia:TI,AB,KY 18
#5 (pelvic adj2 pain):TI,AB,KY 840
#6 #1 OR #2 OR #3 OR #4 OR #5 2111
#7 MESH DESCRIPTOR Anti-Inflammatory Agents, Non-Steroidal EXPLODE ALL TREES 14868
#8 MESH DESCRIPTOR Cyclooxygenase 2 Inhibitors EXPLODE ALL TREES 887
#9 (nonsteroidal* or non steroidal*):TI,AB,KY 8816
#10 nsaid*:TI,AB,KY 2886
#11 (COX 2 or COX-2 or COX2):TI,AB,KY 896
#12 (diclofenac or flurbiprofen or ibuprofen or meclofenamic acid or mefenamic acid or naproxen or 
aspirin):TI,AB,KY 16304
#13 (etoricoxib* or lumiracoxib* or parecoxib*):TI,AB,KY 542
#14 (rofecoxib* or valdecoxib*):TI,AB,KY 509
#15 (acemetacin or celecoxib or dexibuprofen or dexketoprofen or indometacin or ketoprofen):TI,AB,KY 2744
#16 (ponstan or voltaren):TI,AB,KY 223
#17 (cyclooxygenase inhibitor* or cyclooxygenase 2 inhibitor*):TI,AB,KY 1665
#18 (sulphonanilide* or flufenamic or nimesulide):TI,AB,KY 386
#19 (salicylate* or sulindac or acetylsalicylic):TI,AB,KY 6178
#20 piroxicam:TI,AB,KY 1051
#21 #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR 
#20 30354
#22 #6 AND #21 89
3 MEDLINE search strategy
From 1946 to 19 October 2016
Ovid platform
1 exp Endometriosis/ (18905) 
2 Endometriosis.tw. (18913) 
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3 dyspareuni$.tw. (3086) 
4 (pelvic adj2 pain).tw. (7661) 
5 dyschezia.tw. (220) 
6 or/1-5 (31643) 
7 exp anti-inflammatory agents, non-steroidal/ or exp aspirin/ or exp diclofenac/ or exp flurbiprofen/ or exp 
ibuprofen/ or exp indomethacin/ or exp ketoprofen/ or exp meclofenamic acid/ or exp mefenamic acid/ or exp 
naproxen/ or exp piroxicam/ or exp cyclooxygenase inhibitors/ or exp cyclooxygenase 2 inhibitors/ (177771) 
8 nonsteroidal$.tw. (20990) 
9 non-steroidal$.tw. (16588) 
10 nsaid$.tw. (21016) 
11 (COX 2 or COX-2 or COX2).tw. (27740) 
12 (diclofenac or flurbiprofen or ibuprofen or meclofenamic acid or mefenamic acid or naproxen or aspirin).tw. 
(65356) 
13 (etoricoxib$ or lumiracoxib$ or parecoxib$).tw. (1135) 
14 (rofecoxib$ or valdecoxib$).tw. (2313) 
15 (acemetacin or celecoxib or dexibuprofen or dexketoprofen or indometacin or ketoprofen).tw. (9277) 
16 (ponstan or voltaren).tw. (406) 
17 (cyclooxygenase inhibitor$ or cyclooxygenase 2 inhibitor$).tw. (6591) 
18 (sulphonanilide$ or flufenamic or nimesulide).tw. (2422) 
19 (salicylate$ or sulindac or acetylsalicylic).tw. (19959) 
20 piroxicam.tw. (2765) 
21 or/7-20 (242543) 
22 6 and 21 (515) 
23 randomized controlled trial.pt. (432907) 
24 controlled clinical trial.pt. (91818) 
25 randomized.ab. (373304) 
26 placebo.tw. (185009) 
27 clinical trials as topic.sh. (180215) 
28 randomly.ab. (265279) 
29 trial.ti. (163329) 
30 (crossover or cross-over or cross over).tw. (71501) 
31 or/23-30 (1098911) 
32 exp animals/ not humans.sh. (4325953) 
33 31 not 32 (1011983) 
34 22 and 33 (86)
4 EMBASE search strategy
From 1974 to 19 October 2016
Ovid Platform
1 exp ENDOMETRIOSIS/ (30469) 
2 endometriosis.tw. (25587) 
3 (pelv$ adj2 pain).tw. (11770) 
4 dyschezia.tw. (417) 
5 dyspareunia.tw. (5383) 
6 or/1-5 (44542) 
7 exp nonsteroid antiinflammatory agent/ (507110) 
8 exp acetylsalicylic acid/ (183969) 
9 exp CELECOXIB/ (18678) 
10 exp DICLOFENAC/ (34108) 
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11 exp ETORICOXIB/ (2430) 
12 exp FLURBIPROFEN/ (7048) 
13 exp ibuprofen/ or exp ketoprofen/ or exp ketorolac/ or exp mefenamic acid/ or exp naproxen/ or exp 
piroxicam/ or exp rofecoxib/ or exp salicylic acid/ or exp valdecoxib/ (100090) 
14 nonsteroidal$.tw. (24626) 
15 non-steroidal$.tw. (22681) 
16 nsaid$.tw. (33773) 
17 exp prostaglandin synthase inhibitor/ or exp cyclooxygenase 2 inhibitor/ (474499) 
18 (COX 2 or COX-2 or COX2).tw. (36253) 
19 (acetylsalicylic acid or celecoxib or diclofenac or etoricoxib).tw. (31334) 
20 (flurbiprofen or ibuprofen or ketoprofen or ketorolac).tw. (24017) 
21 (mefenamic acid or naproxen or piroxicam or rofecoxib or salicylic or valdecoxib).tw. (25457) 
22 (sulphonanilide$ or flufenamic or nimesulide).tw. (3217) 
23 (ponstan or voltaren).tw. (2942) 
24 (acemetacin or dexibuprofen or dexketoprofen or indometacin).tw. (1861) 
25 (cyclooxygenase inhibitor$ or cyclooxygenase 2 inhibitor$).tw. (7200) 
26 or/7-25 (574498) 
27 6 and 26 (1737) 
28 Clinical Trial/ (978910) 
29 Randomized Controlled Trial/ (454730) 
30 exp randomization/ (83085) 
31 Single Blind Procedure/ (26186) 
32 Double Blind Procedure/ (135680) 
33 Crossover Procedure/ (53307) 
34 Placebo/ (319417) 
35 Randomi?ed controlled trial$.tw. (146931) 
36 Rct.tw. (21980) 
37 random allocation.tw. (1611) 
38 randomly allocated.tw. (26329) 
39 allocated randomly.tw. (2198) 
40 (allocated adj2 random).tw. (842) 
41 Single blind$.tw. (18462) 
42 Double blind$.tw. (171618) 
43 ((treble or triple) adj blind$).tw. (626) 
44 placebo$.tw. (245414) 
45 prospective study/ (380568) 
46 or/28-45 (1749996) 
47 case study/ (91637) 
48 case report.tw. (320145) 
49 abstract report/ or letter/ (980824) 
50 or/47-49 (1383573) 
51 46 not 50 (1700346) 
52 27 and 51 (481)
5 PsycINFO search strategy
From 1806 to 19 October 2016
Ovid Platform
1 exp Gynecological Disorders/ (1613) 
2 endometriosis.tw. (206) 
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3 (pelv$ adj2 pain).tw. (517) 
4 dyspareunia.tw. (527) 
5 or/1-4 (2611) 
6 exp Aspirin/ (438) 
7 exp Analgesic Drugs/ (17453) 
8 (non?steroidal adj5 anti?inflammatory).tw. (86) 
9 (non-steroidal$ adj5 anti-inflammatory).tw. (460) 
10 nsaid$.tw. (799) 11 (COX 2 or COX-2).tw. (733) 
12 (acetylsalicylic acid or celecoxib or diclofenac or etoricoxib).tw. (594) 
13 (flurbiprofen or ibuprofen or ketoprofen or ketorolac).tw. (627) 
14 (mefenamic acid or naproxen or piroxicam or rofecoxib or salicylic acid or valdecoxib).tw. (341) 
15 aspirin.tw. (1033) 
16 or/6-15 (20157) 
17 5 and 16 (31)
6 CINAHL search strategy
From 1982 to 19 October 2016
Ebsco platform
# Query Results
S42 S29 AND S41 40
S41 S30 OR S31 OR S32 OR S33 OR S34 OR S35 OR S36 OR S37 OR S38 OR S39 OR S40 1,081,306
S40 TX allocat* random* 5,281
S39 (MH "Quantitative Studies") 14,919
S38 (MH "Placebos") 9,827
S37 TX placebo* 39,650
S36 TX random* allocat* 5,281
S35 (MH "Random Assignment") 41,699
S34 TX randomi* control* trial* 110,746
S33 TX ( (singl* n1 blind*) or (singl* n1 mask*) ) or TX ( (doubl* n1 blind*) or (doubl* n1 mask*) ) or TX ( (tripl* n1 blind*) or (tripl* n1 mask*) ) or TX ( (trebl* n1 blind*) or (trebl* n1 mask*) ) 857,082
S32 TX clinic* n1 trial* 190,012
S31 PT Clinical trial 79,719
S30 (MH "Clinical Trials+") 203,397
S29 S6 AND S28 104
S28 S7 OR S8 OR S9 OR S10 OR S11 OR S12 OR S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22 OR S23 OR S24 OR S25 OR S26 OR S27 30,886
S27 TX piroxicam 209
S26 TX(salicylate* or sulindac or acetylsalicylic) 1,237
S25 TX(sulphonanilide* or flufenamic or nimesulide) 100
S24 TX(cyclooxygenase inhibitor* or cyclooxygenase 2 inhibitor*) 801
Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis 02-Feb-2017
Review Manager 5.3 26
S23 TX(ponstan or voltaren) 28
S22 TX(acemetacin or celecoxib or dexibuprofen or dexketoprofen or indometacin or ketoprofen) 1,030
S21 TX(rofecoxib* or valdecoxib*) 520
S20 TX(etoricoxib* or lumiracoxib* or parecoxib*) 316
S19 TX(diclofenac or flurbiprofen or ibuprofen or meclofenamic acid or mefenamic acid or naproxen or aspirin) 14,883
S18 TX (COX 2 or COX-2 or COX2) 5,065
S17 TX nsaid* 3,651
S16 TX nonsteroidal* or TX non steroidal* 12,754
S15 (MM "Cox-2 Inhibitors") 1,857
S14 (MM "Piroxicam") 104
S13 (MM "Naproxen") 269
S12 (MM "Ketorolac") 273
S11 (MM "Indomethacin") 450
S10 (MM "Ibuprofen") 798
S9 (MM "Diclofenac") 566
S8 (MM "Aspirin") 4,207
S7 (MM "Antiinflammatory Agents, Non-Steroidal+") 12,096
S6 S1 OR S2 OR S3 OR S4 OR S5 5,662
S5 TX (pelvic N2 pain) 2,557
S4 TX dyschezia 19
S3 TX dyspareuni* 916
S2 TX Endometriosis 2,764
S1 (MM "Endometriosis") 1,702
